Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
PHD1, PHD2, PHD3 Enzyme Assay from US Patent US11981669: "1,7-naphthyridine derivative and preparation method and use therefor"
Assay data:5 Active, 5 Activity ≤ 1 µM, 5 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by DepositorRelated BioAssays by Target
Inhibition of C-terminal MYC/DDK tagged full length human PHD2 using 19 mer peptide substrate DLDLEMLAPYIPMDDDFQL incubated for 30 mins by MALDI-based assay
Assay data:1 Tested
SummaryPubMed CitationRelated BioAssays by Target
Inhibition of N-terminal truncated PHD2 (unknown origin) by luminescence based assay
Inhibition of PHD2 (unknown origin)
Assay data:2 Active, 2 Tested
SummaryCompounds, ActivePubMed CitationRelated BioAssays by Target
Inhibition of N-terminal His-tagged human PHD2 catalytic domain (181 to 426 residues) expressed in Escherichia coli
Assay data:2 Tested
Inhibition of human PHD3 expressed in H5 insect cells
Assay data:5 Tested
Inhibition of human PHD2 expressed in H5 insect cells
Inhibition of human PHD1 expressed in H5 insect cells
PHD2 Enzymatic Assay from US Patent US11780854: "Prolyl hydroxylase domain-containing protein (PHD) inhibitors and uses thereof"
Assay data:14 Active, 14 Activity ≤ 1 µM, 15 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by Target
Vitro Assays Demonstrate PHD Inhibition from US Patent US20230295110: "PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE"
Assay data:67 Active, 62 Activity ≤ 1 µM, 67 Tested
In Vitro Kinase Activity Assay from US Patent US11691950: "Isoquinoline-steroid conjugates and uses thereof"
Assay data:21 Active, 18 Activity ≤ 1 µM, 21 Tested
Pharmacological Activity Assay from US Patent US11655249: "Indolizine derivatives and their application in medicine"
Assay data:17 Active, 11 Activity ≤ 1 µM, 23 Tested
Enzyme Activity Assay from US Patent US11618744: "Benzoimidazoles as prolyl hydroxylase inhibitors"
Assay data:182 Active, 177 Activity ≤ 1 µM, 186 Tested
Inhibition of PHD2 (unknown origin) at 66.7 uM relative to control
Assay data:12 Tested
Inhibition of PHD2 in human Hep3B cells assessed as increase in EPO production at 5 uM measured after 24 hrs by ELISA
Inhibition of PHD2 in human Hep3B cells assessed as stabilization of HIF-1alpha at 100 uM incubated for 4 hrs
Assay data:5 Active, 5 Tested
Inhibition of PHD2 in human Hep3B cells assessed as stabilization of HIF-2alpha at 100 uM incubated for 4 hrs
Inhibition of PHD2 in human Hep3B cells assessed as increase in EPO production measured after 24 hrs by ELISA
Assay data:10 Active, 3 Activity ≤ 1 µM, 10 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Inhibition of recombinant N-terminal hexahistidine-tagged human PDH2 (181 to 426 residues) expressed in Escherichia coli BL21 (DE3) preincubated for 15 mins followed by substrate addition and measured after 15 mins using CODD peptide DLDLEMLAPYIPMDDDFQL as substrate by SPE-MS-based assay
Assay data:5 Active, 12 Tested
Inhibition of N-terminal His tagged PHD2 (181 to 426 residues) (unknown origin) measured by MALDI-TOF MS analysis
Assay data:3 Active, 3 Activity ≤ 1 µM, 3 Tested
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on